Bone marrow transplantation vol:17 issue:1 pages:115-7
A 43-year-old woman developed life-threatening refractory thrombocytopenia following autologous peripheral blood stem cell transplantation for metastatic breast carcinoma. Anti-PLA1 antibodies were demonstrated in the patient's plasma. Treatment with intravenous immunoglobulin and transfusion of PLA1-negative blood products restored platelet responsiveness. PLA1 allo-antibodies should be considered as a possible cause of severe refractory thrombocytopenia in marrow transplant patients. It is important to make this diagnosis as the mainstay of treatment is the avoidance of blood products from PLA1-positive donors (98% of the population).